CA
NZ
UK
AU
IND
US
In Sustainable Technology Solutions, revenue rose USD 157 million to USD 762 million and adjusted EBITDA increased 15% to USD 147 million. The margin of 19.3% compared with 21.2% a year earlier because of a larger liquefiedNatural Gasjoint venture contribution in the prior period. …
The earnings jump leaned heavily on a USD 89.4 million gain on sale of properties, against USD 3.7 million a year earlier. Interest expense rose to USD 87.7 million from USD 84.3 million, andImpairmentcharges were USD 8.0 million. On an operating basis, FFO of …
Research and development expense reached USD 128.5 million, up from USD 74.1 million. STAT6 external costs were USD 52.0 million versus USD 17.4 million, other external costs were USD 31.0 million, personnel costs were USD 30.3 million and overhead was USD 15.1 million. General …
Chief Executive Officer Eilif Serck-Hanssen said revenue and adjusted EBITDA of USD 147 million both came in above the guidance given three months earlier, helped by favorable currency. The chief financial officer put the currency lift to revenue at USD 29 million and said …
Royalty revenue reached USD 70.3 million versus USD 46.6 million, with growth attributed to the newly acquired XOMAAssetsand to products such as Filspari from Travere Therapeutics and Ohtuvayre from Merck. Captisol sales slipped to USD 7.9 million from USD 10.7 million on customer order …
Operating income increased 27% to USD 786 million, andOperating Marginwidened 200 basis points to 13%. Chief Executive Officer Sam Mehta tied the result to execution and pointed to aBacklogaligned with missiles, space, resilient communications and electronic warfare, and multi-domain sensing.
Adjusted operating profit grew 8% to USD 2.76 billion, while reported operating profit fell 9% to USD 2.15 billion.
The GAAP result includes USD 111 million of pre-tax non-cash charges, made up of a USD 88 millionGoodwillimpairment in the Specialty segment and USD 23 million tied to netAssetsheld for sale in Romania. Adjusted net income was USD 127 million versus USD 216 million. …
Revenue growth of 39% combined a 53% volume gain with a 15% price decline. Mounjaro revenue rose 65% to USD 10.72 billion, with U.S. sales up 41% and sales outside the U.S. up 93%. Zepbound reached USD 5.35 billion, up 49%. Cardiometabolic health revenue …
LNG revenues were USD 6,099 million. Sales from the liquefaction projects under third party long term agreements brought in USD 4,027 million, up from USD 3,481 million, while short term sales by the integratedMarketingfunction rose to USD 1,876 million from USD 630 million. Total …
Please wait processing your request...